Drug intelligence / Profile preview

F008

Development stage: Unknown
Lead developer: Shandong New Time Pharmaceutical
Administration: Intravenous

Overview

F008 is an investigational drug currently undergoing a Phase I clinical study to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. The drug is being developed for the treatment of Acute Ischemic Stroke (AIS) and is administered intravenously. The clinical development is a collaborative effort between West China Hospital of Sichuan University and Shandong New Times Pharmaceutical Co., LTD.

Beyond the preview

Go deeper on F008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F008.

Explore the full profile